Article Text

Download PDFPDF

Communication
Low grade mosaicism in hereditary haemorrhagic telangiectasia identified by bidirectional whole genome sequencing reads through the 100,000 Genomes Project clinical diagnostic pipeline
  1. Jessica M Clarke1,2,
  2. Mary Alikian1,2,
  3. Sihao Xiao2,3,
  4. Dalia Kasperaviciute4,
  5. Ellen Thomas1,4,
  6. Isobel Turbin1,3,
  7. Kike Olupona1,
  8. Elna Cifra1,
  9. Emanuel Curetean1,
  10. Teena Ferguson1,
  11. Julian Redhead1,
  12. The Genomics England Research Consortium4,
  13. Claire L Shovlin1,2,3
  1. 1 West London Genomic Medicine Centre, Imperial College Healthcare NHS Trust, London, UK
  2. 2 Genomics England Respiratory Clinical Interpretation Partnership (GeCIP), London, UK
  3. 3 NHLI Cardiovascular Sciences, Imperial College London, London, UK
  4. 4 Genomics England, London, UK
  1. Correspondence to Claire L Shovlin, Professor of Practice (Clinical and Molecular Medicine), NHLI Vascular Science, Imperial Centre for Translational and Experimental Medicine (ICTEM), Hammersmith Campus, London W12 0NN, UK; c.shovlin{at}imperial.ac.uk

Statistics from Altmetric.com

Whole-genome sequencing (WGS) has been championed within the UK National Health Service (NHS) and represents one of the approaches within the forthcoming UK National Genomic Test Directory to identify genetic variants that cause particular rare inherited diseases.1

Although diploid organisms such as man develop from a single cell, postzygotic somatic mutations occur and lead to mosaicism.2 Sufficiently early generation of a disease-causing DNA sequence variant can result in a mosaic individual who is the first member of a family to be affected by an inherited disorder.3 4 Their causative DNA sequence variant is likely to be present at less than the 50% expected for a heterozygote, and may be difficult to detect with confidence. Greater ability to detect mosaicism has been used to favour higher depth panel-based sequencing rather than WGS as, due to sequencing capacities, there are trade-offs between the number of target nucleotides sequenced and the average depth of reads at any given nucleotide.

It is increasingly recognised that hereditary haemorrhagic telangiectasia (HHT5) is a condition where the first affected member of the family may be a mosaic.3 4 HHT is transmitted as an autosomal dominant trait via a single pathogenic DNA sequence variant, usually in ENG, ACVRL1 or SMAD4.5 There are hundreds of different pathogenic variants in these genes in different HHT families, all resulting in similar clinical features.6 HHT is diagnosed clinically by the presence of at least three Curaçao Criteria: recurrent nosebleeds, mucocutaneous telangiectasia, visceral involvement such as pulmonary, hepatic, gastrointestinal or cerebral arteriovenous malformations (AVMs), and an affected first-degree relative.5 A high index of suspicion for HHT is warranted, particularly in cases where more than one AVM is present or where multiple generations display these features. As we have shown, however, high proportions of referrals to mainstream services with pulmonary AVMs have no identified HHT causal genes on standard gene testing, even when there is clear evidence of HHT clinically.7

The proband was one of these7 cases, a 54-year-old woman who had presented following major complications from pulmonary AVMs including a cerebral abscess and profound hypoxaemia. The pulmonary AVMs were treated by embolisation, and she was also advised to use antibiotic prophylaxis prior to future dental and surgical procedures.5 On clinical assessment, she reported frequent nosebleeds and displayed characteristic HHT buccal mucosal telangiectasia. There was no antecedent family to suggest HHT across an extensive family history, although several individuals in the subsequent generations experienced nosebleeds. Fulfilling three Curaçao Criteria, the proband received a clinical diagnosis of ‘Definite HHT’. Descendants with nosebleeds had two Curaçao Criteria and received a label of ‘Possible HHT’. Using routine methodologies and processes including bidirectional Sanger sequencing, HHT gene testing for ENG, ACVRL1 and SMAD4 did not identify a genetic cause for disease in the proband. Due to the absence of a molecular test for the family, the condition could not be excluded in any descendants.

The proband was recruited to the 100,000 Genomes Project.8 Following WGS of DNA extracted from a second sample of peripheral blood and sequence alignment to Genome build GRCh38 and ENST00000373203, the recruiting Genomic Medicine Centre (GMC) was informed that she had a Tier 2 variant in ENG, the gene most commonly responsible for pulmonary AVM-associated HHT. The synonymous variant ENG c.1134G>A, p.(Ala378=), rs1329127701, has a Genome Aggregation Database (gnomAD) frequency of 0.00003, substitutes an A for the final G of ENG exon 8, and is predicted by five splicing programmes to reduce splice site efficiency by a mean of 33% (figure 1). The variant is listed as pathogenic on the HHT Mutation Database,6 and ClinVar.9 At the multidisciplinary team meeting, it was concluded that the variant could explain the patient’s phenotype, and DNA was sent for Sanger sequencing validation.

Figure 1

Variant consequences: (A) schematic of variant ENG (NM_001114753) c.1134G>A, p.(Ala378=) and (B) splice site predictions: the symbols indicate from highest to lowest, the percentage (%) reduction in splice site efficiency calculated by SpliceSiteFinder-like, MaxEntScan, NNSPLICE, GeneSplicer and HumanSplicingFinder. All five exceeded the 10% reduction considered significant, and three exceeded 30% reduction. The variant therefore meets sufficient American College of MedicalGenetics and Genomics (ACHG) / Association for Molecular Pathology (AMP) criteria10 to be classified as ‘likely pathogenic’: 1 strong criterion (Ps4: Genome Aggregation Database frequency 0.00003), plus ≥2 supporting criteria (PP3: predicted by five splicing programmes to reduce splice site efficiency; PP4: highly specific patient phenotype; and PP5: listed as pathogenic on two reputable sources7 9).

As in the original NHS gene test however, the variant was not initially confirmed by Sanger sequencing, and the case was referred to the Respiratory Genomics England Clinical Interpretation Partnership.

Careful review of traces on Genomics England’s Integrative Genomics Viewer indicated that the variant nucleotide was not present at the 50:50 distribution expected for an autosomal dominant disorder (figure 2A). The variant was identified on forward and reverse reads, suggesting it was unlikely to be a sequencing artefact (figure 2B). Subsequent Sanger sequencing identified the signal from the variant nucleotide at a level that could be easily disregarded as background noise in Sanger-based testing without prior knowledge (figure 2C).

Figure 2

Variant detection: (A) of the 35 reads at Chr9:127 824 304 (arrowed), 28 (80%) were wild type and 7 (20%) were the variant sequence; (B) of the 18 forward strand reads, 16 (88.9%) were wild type, 2 (11.1%) were variant. Of the 17 reverse strand reads, 12 (70.6%) were wild type and 5 (29.4%) were variant. (C) The clean Sanger sequencing trace at the locus demonstrating wild-type (black) and variant (green) sequences. The wild-type peak was quantified as 793 RFUs, compared with the variant peak of 121 RFUs representing 15.3% of the total. RFU, relative fluorescence unit.

The 100,000 Genomes Project operates using a second alignment and filtering pipeline for research interrogations. The same weighting of signal:noise escape might be viewed less favourably if applied genome wide than for clinical diagnostic sequencing where a single rare variant is sought in one of the RefSeq genes. We therefore reviewed the individual’s variant call format (vcf) file in the Genomics England Research Environment where raw sequencing data had been separately analysed by Illumina Issac for sequence alignment and Starling for small variant calling.8 The variant was not identified in these more stringent pipelines.

We concluded that ENG c.1134G>A, p.(Ala378=) was confirmed in the proband and represents a further case of mosaicism in the first clinically affected member of an HHT family.3 4 This case also allowed us to conclude that the set of automated pipelines in place through the 100,000 Genomes Project for clinical diagnostic purposes are able to identify low-grade mosaicism. The clinical diagnostic algorithms used Platypus, which employs an allele bias filter for variants based on expectation under heterozygous segregation in a diploid organism. However, Platypus rejects variants only if the fraction of variant reads is less than 0.5 and the p value under a binomial model is less than 0.001. In other words, the fraction of variant reads that trigger this filter depends on the total coverage, and as we have shown, for a read depth of 35, a fractional read of 0.2 will escape the filter, increasing the likelihood of detecting pathogenic variants present in mosaics. We suggest such potential mosaic calls could be highlighted to GMCs to facilitate the necessary rigorous Sanger sequence inspections.

On a wider note, there are two important general implications. The first is the message that mosaicism should be kept in mind in cases of inherited diseases such as HHT where no pathogenic variant is identified; other methods to look for mosaicism, for example, examination of an oral mucosa swab, or tissue targeted methods may be considered. Second, the case highlights that traditional Sanger sequencing is unreliable when it comes to mosaic cases. Even with only modest coverage (35X), WGS with a robust bioinformatics pipeline clearly identified the pathogenic variant. Recognising that the cost of next generation sequencing is continuously going down, and throughput is continually going up, we would recommend next-generation sequencing for all clinical testing.

Acknowledgments

This research was made possible through access to the data and findings generated by the 100,000 Genomes Project. The 100,000 Genomes Project is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The 100,000 Genomes Project uses data provided by patients and collected by the NHS as part of their care and support. We thank the NHS staff of the UK Genomic Medicine Centre and the family for their willing participation.

References

View Abstract

Footnotes

  • Genomics England Research Consortium Ambrose J. C. 1, Arumugam P.1, Baple E. L. 1, Bleda M. 1, Boardman-Pretty F. 1,2, Boissiere J. M. 1, Boustred C. R. 1, Brittain H.1, Caulfield M. J.1,2, Chan G. C. 1, Craig C. E. H. 1, Daugherty L. C. 1, de Burca A. 1, Devereau, A. 1, Elgar G. 1,2, Foulger R. E. 1, Fowler T. 1, Furió-Tarí P. 1, Hackett J. M. 1, Halai D. 1, Hamblin A.1, Henderson S.1,2, Holman J. E. 1, Hubbard T. J. P. 1, Ibáñez K.1,2, Jackson R. 1, Jones L. J. 1,2, Kasperaviciute D. 1,2, Kayikci M. 1, Lahnstein L. 1, Lawson K. 1, Leigh S. E. A. 1, Leong I. U. S. 1, Lopez F. J. 1, Maleady-Crowe F. 1, Mason J. 1, McDonagh E. M. 1,2, Moutsianas L. 1,2, Mueller M. 1,2, Murugaesu N. 1, Need A. C. 1,2, Odhams C. A. 1, Patch C. 1,2, Perez-Gil D. 1, Polychronopoulos D. 1, Pullinger J. 1, Rahim T. 1, Rendon A. 1, Riesgo-Ferreiro P.1, Rogers T. 1, Ryten M. 1, Savage K. 1, Sawant K. 1, Scott R. H. 1, Siddiq A. 1, Sieghart A. 1, Smedley D. 1,2, Smith K. R. 1,2, Sosinsky A. 1,2, Spooner W. 1, Stevens H. E. 1, Stuckey A. 1, Sultana R. 1, Thomas E. R. A. 1,2, Thompson S. R. 1, Tregidgo C. 1, Tucci A. 1,2, Walsh E. 1, Watters, S. A. 1, Welland M. J. 1, Williams E. 1, Witkowska K. 1,2, Wood S. M. 1,2, Zarowiecki M. 1. 1, Genomics England, London, UK 2. William Harvey Research Institute, Queen Mary University of London, London, EC1M 6BQ, UK.

  • Contributors KO, EC, TF, JR and CLS contributed to the project set-up at West London Genomic Medicine Centre and patient recruitment; the Genomics England Research Consortium performed the whole-genome sequencing; JMC, MA, SX, DK, ET, IT and CLS contributed to specific data analyses; CLS wrote the first mansucript draft; JMC, MA and DK contributed to manuscript revisions. All authors reviewed and approved the final manuscript. CLS was responsible for the overall content as guarantor.

  • Funding The 100,000 Genomes Project is funded by the National Institute for Health Research (NIHR), National Health Service (NHS) England, Wellcome Trust, Cancer Research UK and the Medical Research Council. The Wellcome Trust, Cancer Research UK and the Medical Research Council also funded research infrastructure. The presented work from West London Genomics Medicine Centre received funding support from NHS England, Imperial College Healthcare NHS Trust and the research was cofunded by the NIHR Imperial Biomedical Research Centre.

  • Competing interests None declared.

  • Patient consent for publication Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.